What the evidence says
The sources agree that circulating sclerostin is higher in people with kidney failure. A 2026 review reports that clinical studies "generally report" elevated levels in CKD, end-stage renal disease and haemodialysis, and a 2023 meta-analysis states that levels are "significantly increased among uremic patients". Neither gives a magnitude. The same review notes that some studies find unchanged or reduced levels, depending on dialysis modality, vitamin D supplementation or serum phosphate. A positive correlation between phosphate and sclerostin has also been reported, but the claims give no sample size or effect size for it. In incident dialysis patients, sclerostin correlates inversely with intact parathyroid hormone (r = -0.25, P < 0.001).
On vascular calcification, the evidence is associational and its direction is inconsistent. One cohort of non-dialysis patients found higher sclerostin in those with aortic calcification (61.92 ± 26.73 vs 45.75 ± 20.84 pmol/L, p = 0.001). The 2026 review says higher sclerostin is "frequently associated" with calcification severity, arterial stiffness and adverse cardiovascular markers in CKD cohorts. It also says higher sclerostin in dialysis patients has been linked to less severe aortic valve and aortic wall calcification in several cohorts. Sclerostin is also expressed locally in calcified tissue, such as calcific aortic stenosis and calciphylaxis lesions, according to work cited in the Drechsler paper. The pooled analysis finds no association with vascular calcification as a continuous measure (OR 1.03, 95% CI 0.99–1.08) or as a categorical one (OR 1.01, 95% CI 0.19–5.35). Heterogeneity was moderate for the continuous analysis (I2 = 57.0%) and extreme for the categorical one (I2 = 94.7%).
For mortality, the cohorts point in opposite directions. In incident dialysis patients, the highest sclerostin tertile had lower cardiovascular mortality within 18 months than the lowest tertile (HR 0.29, 95% CI 0.13–0.62). In a non-dialysis cohort, each 10 pmol/L increase in sclerostin came with 31% higher cardiovascular mortality (sub-distribution HR 1.31, 95% CI 1.085–1.581, p = 0.005). That same cohort found no association with non-cardiovascular mortality (sub-distribution HR 1.292, 95% CI 0.734–2.274). Pooled across CKD studies, sclerostin shows no measured association with all-cause mortality (HR 0.71, 95% CI 0.42–1.19, I2 = 81.0%).
The only mechanism on the page is a hypothesis. The review proposes that raised circulating sclerostin in dialysis "may represent a compensatory response", with higher local expression at calcifying sites restraining pathological Wnt signalling. The source presents this as a way to reconcile conflicting observational findings, not as a measured result. No claim here tests whether sclerostin causes or prevents calcification. All the evidence is observational.
Where the evidence splits
Direction of the sclerostin–calcification link. The review reports that higher sclerostin tracks with more severe calcification in CKD cohorts. It also reports that higher sclerostin in dialysis patients tracks with less severe aortic valve and aortic wall calcification. The pooled meta-analysis finds no association in either of its primary analyses. The sources on this page do not explain the split with a difference in design or population. The review's compensatory-response idea is a speculative proposal and was not tested.
Sensitivity analysis flips the pooled results. Excluding one study whose outcome was arteriovenous fistula calcification changes the pooled calcification estimate to OR 2.16 (95% CI 1.18–3.94). For all-cause mortality, the pooled HR moves from 0.71 (95% CI 0.42–1.19) to 0.59 (95% CI 0.46–0.76) after excluding one study. The claims do not name the excluded study for mortality, and do not say whether the exclusion is clinically justified. Heterogeneity was high in the original pooled estimates.
Cardiovascular mortality runs in opposite directions. The incident-dialysis cohort finds lower cardiovascular mortality with high sclerostin (HR 0.29). The non-dialysis cohort finds higher cardiovascular mortality per 10 pmol/L (sub-distribution HR 1.31). The two differ in population: the second cohort excluded dialysis patients, enrolled 130 participants (about 19 cardiovascular deaths) and was limited to Caucasian participants. They also differ in follow-up, 18 months against 7–8 years, and in the statistical model. The claims do not say which difference, if any, explains the split.
Whether levels are elevated in dialysis. The review reports elevated levels in general, but also unchanged or reduced levels in some investigations. It names modality, vitamin D supplementation and serum phosphate as factors. It does not say which conditions produce which direction.